The total return over the past 12 months is +130.94% vs. +16.94% for the S&P 500. So far it's up +195.26% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +130.94% | +46.63% | +24.57% | N/A | N/A | N/A |
| Total Return CAGR | +130.94% | +46.63% | +24.57% | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Enliven Therapeutics, Inc. (ELVN)
| Year | Start price | End price | ELVN Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $15.40 | $45.47 | +195.26% | +14.51% | +180.75% |
| 2025 | $22.50 | $15.40 | (31.56%) | +17.72% | (49.28%) |
| 2024 | $13.84 | $22.50 | +62.57% | +24.89% | +37.68% |
| 2023 | $16.36 | $13.84 | (15.40%) | +26.19% | (41.59%) |
| 2022 | $9.00 | $16.36 | +81.78% | (18.17%) | +99.95% |
| 2021 | $88.20 | $9.00 | (89.80%) | +28.74% | (118.54%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
